🎁 Black Friday: up to 50% off of annual plans
MaxCyte, Inc. (MXCT)
NASDAQ: MXCT ¡ Real-Time Price ¡ USD
1.370
+0.090 (7.03%)
At close: Nov 20, 2026, 4:00 PM EST
1.350
-0.020 (-1.46%)
After-hours: Nov 20, 2026, 7:03 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

Akron Bio expands reagent offerings and is expected to lift next year’s revenue above $60 million while reducing cash burn to below $10 million. Core markets are stabilizing, with instrument demand, recurring revenue, and large-pharma opportunities supporting expected growth.

Dan Arias
Analyst, Stifel

Okay, here we go. We are going to finish out the day at the Stifel 2026 Healthcare Conference on the life sciences side. We are happy to have MaxCyte with us, CEO Maher Masoud, CFO Parmeet Ahuja. Gentlemen, thanks very much for spending some time with us today.

Maher Masoud
CEO, MaxCyte

Dan, thanks for having us.

Parmeet Ahuja
CFO, MaxCyte

Thank you, Dan.

Dan Arias
Analyst, Stifel

I think, Maher, the most logical place to start would be with the acquisition that you made this week, Akron Bio. Sizeable deal, $150 million. Maybe you can just talk a little bit about that deal, why you did it, and why you think it is an important addition to the company.

Maher Masoud
CEO, MaxCyte

Yeah, great question, Dan, and couldn't be more excited about this transaction, this deal, really. Akron is a leading cytokine growth factor ancillary reagent company, a 20-year-old company. They've really built themselves as best-in-class reagents, no different than how MaxCyte is best-in-class electroporation platform, and it really does for us, it strengthens us in the ex vivo market. What Akron has, their reagents are used throughout ex vivo cell therapy, whether it's viral or non-viral. If you look at where they are, they're led by really a great leadership team already. Ezequiel Zylberberg is the Head of Operations there. Dave Smith, industry veteran, is the Head of Commercial there, President and CCO. They've grown this company over the years from 2018 all the way until now at 13% year-over-year growth, consistent growth.

They're spec'd into four commercial therapies right now, one of them from a large pharma where they've had consistent revenue growth, very durable revenue growth. What it does for us, it broadens our breadth of offerings, truly broadens our breadth of offerings. Their reagents are used pre and post-engineering in the non-viral space, that's pre and post our electroporation systems. In the viral space for cell therapy, which is where predominantly most of the reagents are used right now, they've become kind of ubiquitous with reagents used for cell engineering. Really, it broadens us. It now deepens us in the ex vivo non-viral space, increases our TAM, where we're also in the viral space as well, where the majority of cell and gene therapies are. That's mostly ex vivo therapies. This was a competitive process. We've known the Akron team for quite some time.

We know Dave, we know Ezequiel, we know the team there. We're at conferences together oftentimes, many conferences together. This was us and a handful of other bidders in there as well, strategics that were really trying to ensure that we're the ones that end up winning the bid process. Jefferies was on one side, marketing them. The Stifel team here was our exclusive advisor, and it really came to light. When the two teams started talking to each other, it was clear that this is the right fit for MaxCyte. This is the right fit for our future growth. This is now a company where together we have the scale that we really never had before. We're going to be $60 million+ in revenues next year. They bring $28 million of revenue. They're EBITDA positive, $7 million-$8 million EBITDA positive, free cash flow.

This is truly an ideal. It's a hand in glove. We can now become that consolidator of the space where we give best-in-class products to cell therapy developers. Their cytokines and reagents, I can go on and on, truly on and on. I mean, they out-compete everyone, and I'm sure you have other questions we can get into, but-

Dan Arias
Analyst, Stifel

Well, I mean, maybe along those lines without going too deep into it, I'd love to just sort of get a sense for the differentiation of the portfolio. I mean, there are other large and small GMP reagent providers

Maher Masoud
CEO, MaxCyte

Sure

Dan Arias
Analyst, Stifel

out there. Where do they make their mark with customers?

Maher Masoud
CEO, MaxCyte

Yeah, absolutely. What they've done over the years, they've built highly stable, high-quality cytokines and growth factors. They have a closed liquid format, so they have a closed system, liquid bags that can be used straight into the manufacturing process. You don't have to have lyophilized products. All their liquid cytokines, growth factors can be stable at refrigerated temperature. No one has that. High quality, highly spec'd into commercial products. They have four other registrational products that could be approved in the very near term as well that they're spec'd into. So really high quality. They have a drug master file that's also referenced by these developers when they're using their ancillary reagents, similar to MaxCyte's drug master file that's used for our electroporation platform. Just best-in-class products, higher quality, high stability.

Truly, they differentiate themselves by doing what they do best, which is in the reagent market, that's all they do. Similar to how MaxCyte does electroporation, we do it better than anybody else. They cannot compete the big guys.

Dan Arias
Analyst, Stifel

Yeah. Okay. I mean, a lot of what you come to like about these deals where small companies with good technologies are acquired is just bringing it to a bigger stage with a bigger sales force and getting it out to a broader base. Can you maybe talk a little bit about what you will do with your own commercial organization, what you will do with their commercial organization, and what sales synergies you think might exist in the next one to two years that is sort of tangible things to look for?

Maher Masoud
CEO, MaxCyte

Absolutely. Absolutely. That was one of the criteria we're looking for is that we have complementary sales and marketing teams here. This is not a case of one competing with the other one. Most of their presence and most of the revenue is from the U.S. We have a fairly large European commercial team that's sales reps as well as field application scientists that really can begin to build up the revenue for them ex-U.S. We have a fairly robust Asia Pacific team as well, both sales reps and field application scientists that can begin to complement Akron's team here as well. And really, it's our reps in the U.S. and their reps in the U.S. kind of just feeding each other and begin to work with each other.

They're a fairly lean team, approximately 45- 50 people that we're going to continue to support and they're going to continue to really do what they do great. We're here to support them. And really, it's a slow integration process. We have gotten the tailwinds behind us as a company. They have their tailwinds. Now's a chance for us to really just work together and just boost our revenues together rather than one replacing the other one. This is complementary sales teams.

Dan Arias
Analyst, Stifel

Okay. All right. Just thinking about where they play and who their customers are. On the call, you mentioned that there's a CAR T player in there. That's one of the commercial relationships.

Maher Masoud
CEO, MaxCyte

It is.

Dan Arias
Analyst, Stifel

The registrational stuff, where are they with those in terms of therapeutic area or subcategory? Then more broadly amongst their customer base, can you just talk about autologous versus allogeneic versus in vivo? Obviously, there's a large conversation about how the industry, cell therapy industry, is shifting within those, so I'd love to just sort of understand that a little bit.

Maher Masoud
CEO, MaxCyte

Yeah, sure. You want me to take that last one first?

Dan Arias
Analyst, Stifel

Yeah.

Maher Masoud
CEO, MaxCyte

On that one, absolutely. If you look at the majority of assets out there, really, it's still ex vivo. That's the majority of assets. These are clinical programs. Vast majority are still ex vivo. In fact, the majority of the in vivo are preclinical programs. You don't have very many clinical programs in vivo. In vivo has a future, and that's mostly on the LNP side. We'll see how that plays out. But if you look at where all the commercial therapies are, if you look at where all the late-stage clinical programs are, those are all ex vivo. And it's usually a split between viral and non-viral based as well. You see a lot of investments going in, some investments beginning to shift a little bit into in vivo, but these are more for preclinical programs.

Really, it's, I believe, you look at LK data, Deci Bio data, whatever data you want to see out there, 90+ some percent are ex vivo therapies. In vivo is less than 10%.

We don't see that shift really moving that much more. In vivo has its own complexity, as we know about. Any safety concerns you've seen have oftentimes been from in vivo clinical programs, not ex vivo programs as much. It's still ex vivo is still a much bigger market then.

Dan Arias
Analyst, Stifel

Yeah. Okay. I'll come back to that one because I just want to ask you about the way that the industry shifts over the next five years or so.

Maher Masoud
CEO, MaxCyte

Sure.

Dan Arias
Analyst, Stifel

But maybe just to stick with Akron and the comment that you made about 13% revenue growth, is there an intention to talk about where you go from here? I mean, we haven't gotten to a 2027 guide yet. Parmeet will give that on the next call. But what level of accretion do you expect from this deal? Then if 13% goes to something higher because of the commercial benefits that we're talking about, what would we think about modeling-wise there? Parmeet, you want to take it?

Parmeet Ahuja
CFO, MaxCyte

Yeah. I mean, the company has done very well from 2018 to now, growing at a CAGR of about 13%. We are certainly expecting that to grow at that same level next year for Akron. Certainly, to your point,

Dan Arias
Analyst, Stifel

Why would that be the case, just out of curiosity? I mean, it looks like there is so much for you guys to do there, and the cell therapies field is

on its way up. I mean, we can debate how much that is the case in certain categories, but why would you not be able to realize a higher level of growth in year one there?

Parmeet Ahuja
CFO, MaxCyte

We could. I mean, right now, they are in four commercial therapies. As they scale, we certainly can see that. If you look at the market data, commercial cell therapies are growing 20%. Overall, including non-commercials, growing about 13%. As that mix changes for Akron, as the commercial programs ramp up, we would start to see more.

Dan Arias
Analyst, Stifel

Okay.

Parmeet Ahuja
CFO, MaxCyte

But I think starting off, we would put that number to early to mid-teens as the right number for them.

Dan Arias
Analyst, Stifel

Okay.

Maher Masoud
CEO, MaxCyte

Do you want me to add to a little bit there as well? Part of it is, again, our commercial team can really begin to boost them. But you begin to see exactly what Parmeet was saying is, we can begin to help them get into more of the preclinical programs, right? But you begin to see the real revenue growth once those programs progress at the commercial side of it. So, until that happens, it is still really their, I would say, traditional growth is what you should be looking at for next year.

Dan Arias
Analyst, Stifel

Okay. And just to clarify, 13% was a CAGR or 13% is what the business grew at?

Maher Masoud
CEO, MaxCyte

This is a CAGR.

Dan Arias
Analyst, Stifel

Okay.

Maher Masoud
CEO, MaxCyte

Yeah.

Dan Arias
Analyst, Stifel

If I presume that things were worse a couple of years ago because the cell therapy markets weren't as robust

then we're at a higher level exiting 2027.

Parmeet Ahuja
CFO, MaxCyte

We don't want to get ahead of our skis yet.

Maher Masoud
CEO, MaxCyte

Skis.

Dan Arias
Analyst, Stifel

My only point is that it feels like you're trying to say that there would be decelerating growth in 2027 on an asset that very obviously has some synergies attached to it by you having it.

Maher Masoud
CEO, MaxCyte

No, I wouldn't say that. I think we don't want to get ahead of our skis right now.

Dan Arias
Analyst, Stifel

Okay. Fair enough.

Parmeet Ahuja
CFO, MaxCyte

Synergies will come.

Dan Arias
Analyst, Stifel

Okay.

Parmeet Ahuja
CFO, MaxCyte

Like Maher said

Maher Masoud
CEO, MaxCyte

Yeah

Parmeet Ahuja
CFO, MaxCyte

it will take a little bit of time.

Dan Arias
Analyst, Stifel

What about cost efficiencies and just what you think you do with the overlap?

Parmeet Ahuja
CFO, MaxCyte

Yeah.

Maher Masoud
CEO, MaxCyte

Yeah.

Parmeet Ahuja
CFO, MaxCyte

It is an OPEX-light asset, Dan. We will see some savings in corporate functions, in G&A. Broadly across the combined organization, we are looking at $3 million-$4 million in cost savings. We think we are going to start to realize that by the time we get to second half of next year. More to come when we guide for the full year.

Dan Arias
Analyst, Stifel

Okay.

Maher Masoud
CEO, MaxCyte

These are just overlap of functions.

Parmeet Ahuja
CFO, MaxCyte

That is right.

Maher Masoud
CEO, MaxCyte

Right? You do not need to have two booths at every conference, so to speak. You see that.

Dan Arias
Analyst, Stifel

Public company costs, et cetera.

Maher Masoud
CEO, MaxCyte

Exactly.

Dan Arias
Analyst, Stifel

Yeah. Okay. Can you maybe just talk a little bit about how this impacts the cash burn? I mean, that has been a part of the conversation on the stock, just where MaxCyte's cash burn goes from here. This certainly helps the cause.

Maher Masoud
CEO, MaxCyte

Absolutely

Dan Arias
Analyst, Stifel

quite a bit. I'd love to just hear the way that you think the next couple of quarters and then the next couple of years roll out.

Parmeet Ahuja
CFO, MaxCyte

Yeah, sure. Great question. So, we started the year giving a $20 million cash burn. We're now expecting with our guide for full year that we gave yesterday, we'll end the year at $17 million, sort of legacy MaxCyte cash burn. Next year, with the addition of Akron as well as our own growth, we expect the cash burn to be below $10 million. And then as revenue grows from there, we'll continue to make progress further down.

Dan Arias
Analyst, Stifel

Okay.

Maher Masoud
CEO, MaxCyte

I want to take a step back as well, Dan. I mean, we've done a lot in the past few years as well. We reduced our own cash burn by more than half as well. Right? So, that stability really has, is continuing on. We're seeing it this year. That allows us to go into next year as well and feel confident that with the Akron's revenue, with our growth as well, we can continue to also get that cash burn even lower. So, we should look back a little bit in the sense of what we did the past few years has really positioned us for the cell therapy growth that's coming in the future years.

Dan Arias
Analyst, Stifel

Okay. Do you see there being areas of integration risk? I mean, every deal has some level of concern when it comes to two companies coming together and then there being the ideal way that they come together and then the realistic way that they come together.

Maher Masoud
CEO, MaxCyte

Sure.

Dan Arias
Analyst, Stifel

What do you see as the mission-critical priorities in areas where the biggest questions lie?

Maher Masoud
CEO, MaxCyte

Sure. Absolutely. There is always integration risk. However, here, because we are buying an established company, a company with true leadership there as well, makes our risk a little bit less. We are not coming in to disrupt what is happening there. They are also spec'd into four commercial programs already, which allows us to really continue that business as it is going as well. As I mentioned, this is a case where these are complementary commercial teams. This is not a commercial team that has to impose its way of doing commercial on Akron or vice versa. So there is risk there, obviously, but an established company with true leadership in Dave Smith and Ezequiel Zylberberg, as well as the operational team there, they have been doing this for 20 years. I think the risk is less than I think many companies do when they have these kind of acquisitions.

Dan Arias
Analyst, Stifel

Okay. 60% or so gross margins.

Maher Masoud
CEO, MaxCyte

That is it.

Dan Arias
Analyst, Stifel

I mean, anybody looking at that would say that is a good number. You have 80% gross margin, so you have a high-class problem when it comes to dilution there. What do you think about getting Akron's gross margins somewhere closer to yours? What are the things that have to happen, and how easy or not easy are those things?

Parmeet Ahuja
CFO, MaxCyte

Yeah. I mean, I would say, first of all, the combined company is going to be at a very healthy early 70s gross margins. So, really, really good. I think as the two companies come together, we start to integrate on the operational side of things.

Very limited in the coming year. This will happen over time, Dan. We certainly see opportunity to improve that further, but again, as you said, very healthy to begin with.

Dan Arias
Analyst, Stifel

Yep. Okay.

Maher Masoud
CEO, MaxCyte

It is also very healthy for MaxCyte, and not many companies have the 80% gross margin.

Dan Arias
Analyst, Stifel

Yeah, you have margin to play with. I mean, I think the P&L on this deal would line up pretty favorably for most people. It is just simply taking the different line items and say, "Okay, this one is higher than this one.

Maher Masoud
CEO, MaxCyte

Right.

Dan Arias
Analyst, Stifel

And so what does that mean?" And just also a question about where the areas are that you Even if it does not get to 80, if it gets to 65 or 70, where does that come from? I mean, I guess maybe that is a question. What are the things that when you looked at the business, you said, "Even though it is run really well by Dave Smith and company,

we see things that we can do." What would those things be?

Parmeet Ahuja
CFO, MaxCyte

I think it is going to be up and down the P&L. A lot of opportunities in the G&A area, as I mentioned earlier. It is a well-run shop from an operations standpoint. I think we will have to get in there to see where those savings would come from. There are things on the MaxCyte side of things that we are also looking at.

More to come on that.

Dan Arias
Analyst, Stifel

Okay.

Parmeet Ahuja
CFO, MaxCyte

That is part of our $3 million-$4 million this coming year, and more to come after that.

Maher Masoud
CEO, MaxCyte

Also, as commercial revenues begin to grow for them and for us, those gross margins also begin to increase as well. That is the natural progression in the future years.

Dan Arias
Analyst, Stifel

Yeah, that makes sense. Okay. All right, we may come back to Akron, because I am sure that will play into just the way that we talk about growth going forward. But I would love to just sort of transition to the MaxCyte side of the business and talk about the way that we see things today. You reported third quarter, it was a very good quarter.

How do you feel about the state of affairs in your markets right now? What measurable evidence would you suggest we think about when it just comes to thinking about stabilization in the market and then where we can go from here?

Maher Masoud
CEO, MaxCyte

Absolutely. I think let's take a step back and look at just, there is a broader market trends that we look at, but then there is also the trends of the funding for our space as well, specifically for the ex vivo space and the cell therapy space itself. 2024 to 2025, relatively stable funding environment for the most part. I think there was 19% growth in terms of funding of clinical programs in 2025 versus 2024, but it was also from selective programs as well. It was less programs funded in 2025, a little bit less. Overall funding more, but it is just showing stability. Dan, this is now 2024, 2025, $3 billion funded in 2024, $3.5 billion funded in 2025. Let's just call it stability there. I do not want to call it that much growth.

We are seeing just programs that are closer to being commercial or later stage, that is where the funding is coming from, and that actually is exactly one of the reasons I keep going back to Akron, acquiring a company like Akron that has so much exposure to the commercial space. And then our exposure as well allows us to begin to capture that growth over the years that the cell therapy space is, as you are seeing. So when you see numbers out there that says 20% growth year-over-year, those are more developed tools companies that are supporting commercial programs. That is where you are seeing that growth come in. We are seeing stability, and I think this is two straight years. We believe 2026 will probably be the same type of funding that they had in 2025.

We are seeing stability here where we can begin to grow from here in the future years.

Dan Arias
Analyst, Stifel

Yeah, said another way, I mean, we just think about where the industry has been over the last couple of years. Program rationalization risk, which has been something that you guys have had to deal with, that feels like it should have at least bottomed right now.

Maher Masoud
CEO, MaxCyte

That is right.

Dan Arias
Analyst, Stifel

And so, barring the unexpected, you would not expect to have to talk about the number of active programs being lower than it has been in the past. You should hopefully be on the way up from here.

Maher Masoud
CEO, MaxCyte

That should be the hope. I mean, right now, we have 13 active programs by 12 developers. These are mostly their lead assets. This is biotech, you are always going to have one or two come here and there, but at the same time, we expect more clinical programs to go into the clinic as well from the therapy developers and pre-clinic right now that we are supporting.

Dan Arias
Analyst, Stifel

Yeah.

Maher Masoud
CEO, MaxCyte

It feels stable right now, Dan.

Dan Arias
Analyst, Stifel

Okay.

Maher Masoud
CEO, MaxCyte

I think the rationalization we saw, or I like to say the culling of programs in 2025, that really, that had an effect on us, that is largely behind us.

Dan Arias
Analyst, Stifel

Great to hear. Okay. On the Q3 quarter, instrument revenues were up pretty big. I think it was like 100% growth for instrumentation, and then consumables were up 20%. On the instrument side, that was helped by Genentech, if I remember correctly, but it was not just Genentech.

Maher Masoud
CEO, MaxCyte

Right.

Dan Arias
Analyst, Stifel

Maybe just talk a little bit about how you feel like the instrument placement is evolving. Based on our comments, it feels like it is just a function of some stability coming back into the markets, but what is your outlook for now placing systems going forward?

Parmeet Ahuja
CFO, MaxCyte

Yeah, I mean, we have been talking about this last couple of quarters. As we looked through our funnel, we saw good instrument pickup happening. Adjusting for Genentech, it was still double-digit growth in Q3. It was a handle starting with seven. It is still early to guide for 2027, Dan, but certainly as we look into the funnel, it is a very broad-based funnel from research through GMP manufacturing, from our GTx, DTx, entire instrument portfolio. I think we will continue to see that as a tailwind moving forward.

Maher Masoud
CEO, MaxCyte

That is right.

Dan Arias
Analyst, Stifel

Okay. On the PA side, what are you seeing in terms of improvements from SPL and non-SPL customers? There were some inventory drawdown issues.

that you guys have dealt with in the past. Fair to say that those are behind you as well? My assumption is yes, but you never know. You want to just make sure that you can check the box on those things. Just talk about the recurring revenue stream from here as well.

Maher Masoud
CEO, MaxCyte

Sure.

Parmeet Ahuja
CFO, MaxCyte

Yeah.

Dan Arias
Analyst, Stifel

Do you want to take that part?

Parmeet Ahuja
CFO, MaxCyte

Very much. I think as you alluded to, the largest customer of ours, that inventory drawdown is behind us. We saw growth there. Even with the other SPL programs, that rationalization of programs you talked about is behind us. We see growth, I would say kind of in the mid-single digit, consistent growth from this stable base is certainly something we'll look at for next year.

Dan Arias
Analyst, Stifel

Okay. Can you just spend a minute on the Genentech deal? I mean, that was

Maher Masoud
CEO, MaxCyte

Sure

Dan Arias
Analyst, Stifel

an interesting move in the sense that there was a switch there. Doesn't happen all the time.

I don't know how much you want to get into that.

I'd love to just sort of conceptually understand what was switched from and why they switched to MaxCyte.

Maher Masoud
CEO, MaxCyte

Certainly.

Dan Arias
Analyst, Stifel

Then what that might mean for deals like it coming down the pike, because it seemed like a proof of principle type thing, but I don't want to get too carried away and just assume that there are going to be others behind it.

Maher Masoud
CEO, MaxCyte

Sure. Absolutely. Let me talk about the switching for a second. This actually, if you remember, Dan, this is now the fourth therapy that we have switched out when they are in phase I trial, from a competing system to our system. I think it speaks to the breadth of our platform, how well it works in the clinic. It speaks to the breadth of our scientific team as well. The Genentech deal, the way it came about was, this was an 18-month process where we are working with them, not just negotiating the contract itself, but really going head-to-head with the current system in the clinic, head-to-head with competing systems to displace that system in the clinic. After 18 months, it was clear our platform is what they are using in the clinic compared to the current platform and compared to other competing platforms.

That has happened, as I mentioned, I believe with three other programs as well, where we displaced programs, competing systems in the clinic for therapeutic products at phase I. This was a relationship we built over the last 18 months, maybe even a little before that as well. It gives us the opportunity now where we can work with them across the breadth of all their programs, preclinical as well as any clinical programs as well. A bit different than our standard SPLs, right? While it does not have the backend royalty, as we mentioned in the past, that we have with the majority of our SPLs, this is an opportunity for us to work with large pharma, and a model that allows us to monetize really the upfront economics much more.

Many more systems in place for all their programs, current or future programs, for all their clinical programs, allows us to participate, and really, I call it have more shots on goal. You are working with a developer that is not just taking one program into the clinic, but has a healthy number of preclinical programs that they can take into the clinic. Really gets us into that large pharma space that we have never been in before.

Dan Arias
Analyst, Stifel

Yeah. Okay. Parmeet, on just, two questions. On the instrument acceptance trajectory for those guys, obviously to our point before, there was a placement number for 3Q.

Parmeet Ahuja
CFO, MaxCyte

Yeah.

Dan Arias
Analyst, Stifel

Will they successively take instruments across the next several quarters? How are the economics structured around the Genentech deal?

Parmeet Ahuja
CFO, MaxCyte

Yeah, let me take the last one. Very lucrative. Obviously, this is a different model from an SPL model. The baby biotechs conserving cash, the licensing model works a lot better for them, comfortable giving up royalties. Large pharma like Genentech, really not a cash challenge, very comfortable with purchases upfront, don't like royalties. So two complementary commercial models. The economics on an overall customer basis, very lucrative with a large pharma like Genentech, and certainly looking forward to more of these to come. In terms of placement further, we certainly expect another bolus of instruments to come in next year. They have just started to install these systems, so we certainly are expecting PA revenue to tick up here in Q4 as well as going into next year, as our FASs start working with them, getting these instruments installed. But multiple systems expecting that next year.

Dan Arias
Analyst, Stifel

Do you think you'll have visibility on those, or is that kind of a, "Let's just hope they don't ask for them right before the quarter?

Parmeet Ahuja
CFO, MaxCyte

No, I think visibility is building in the funnel, a little bit early at this stage, given that they've had a bolus of purchases, but certainly more to come next year.

Dan Arias
Analyst, Stifel

Okay. All right. You made a comment that you expect more of these to come. Is that to say that, it's easy to say that this is proof of principle and that others will follow behind it, but do you see your sales funnel reflecting this, and do you think that there are, I don't know if you want to call this an enterprise deal, but it's a large deal.

Do you think that we start to see more of those, maybe not over the near term, but the mid-term?

Maher Masoud
CEO, MaxCyte

I do think so. With large pharma, I do think so. The reason being is we now have, it's a proof of concept, right? That's what it is. It also has validated us. A company like Genentech is willing to work with us in the clinic and preclinical, and we have a model now that can work, right? So the SPL model is always going to be part of our business model for small to mid biotechs. But this large enterprise model, which we call the pharma model, I think can really begin to get us into those companies as well. Granted, Dan, you have less large pharma in this space than the baby biotechs, so you have a handful, maybe two handfuls of pharma that will be in this space. But the goal is to begin to really mimic this for every year from here on out.

Dan Arias
Analyst, Stifel

Okay. What do you think your exposure, you mentioned the baby biotechs, what is a good number for us to use on exposure to small biotech? Obviously, that comes up in conversation when you go several quarters and the financing activity doesn't look good, or all of a sudden you start thinking about who might get frugal with their money. I mean, that's a conversation across the space. What would you say a number for you guys would be?

Maher Masoud
CEO, MaxCyte

Probably me on the spot, just the number. I mean, if you look at right now, our stand in terms of exposure right now, our largest customer is roughly 27% of our revenue. Our exposure, one-third is from a large customer, a large pharma customer. I'd say it's probably less than 30% is from small baby biotech. The rest is from large pharma, mid biotech companies. If you look at our SPL programs as well, you look who we're working with, we're working with very well-funded companies. That's why it's 13 programs from 12 companies. It's less than, I'd say, 25% is from small biotech.

Dan Arias
Analyst, Stifel

Okay.

Maher Masoud
CEO, MaxCyte

Yeah.

Dan Arias
Analyst, Stifel

Okay. Parmeet, Q3 will have been the first quarter of growth in a while, and up more than we were thinking. I mean, that was a beat for sure, a couple million. How do you feel about just sort of the trajectory of growth quarterly? Obviously, you want the business to grow annually, and you know that there's lumpiness inherent in some of the quarters, but it also is nice when you get positive and you stay positive on a quarterly basis. Is that something that, without guidance for 2027-

Maher Masoud
CEO, MaxCyte

Yeah

Dan Arias
Analyst, Stifel

you think we can roughly kind of assume is a fair possibility at this point?

Parmeet Ahuja
CFO, MaxCyte

Yeah. I mean, first of all, we expect to grow next year, for sure, right? The objective we laid out at the beginning of the year, we knew coming into the year, first half will be challenging. Second half, we were expecting growth. We were expecting low single-digit growth. Obviously, with this guide, we'll be 15% second half. Some of the tailwinds that we have seen here are expected to continue. I talked about the instrument funnel being very robust across research and GMP manufacturing. PA strength is there. Inventory drawdowns are behind us. At this point, we're focused on executing for Q4, making that happen, but certainly expect to grow next year.

Dan Arias
Analyst, Stifel

Okay. Maher, is the size of the commercial organization changing in a way that a greater number of reps is allowing for you guys to have a better sales funnel, or is the sales funnel improvement really strictly a function of the operating environment and just what's going on out there?

Maher Masoud
CEO, MaxCyte

I think it's a combination of both in the sense of, we've brought in some top leadership here from Sartorius, from STEMCELL Technologies, from Thermo, GE Healthcare. That's in the U.S. and Europe, as well as in Asia Pacific as well. It's also the stability of the space itself is allowing our reps to really go out there, our FAS to go out there and get the traction that we need. There were some things there that were just out of our control in 2025. We lost programs that we could not control in the clinic that affect our revenue. That also is now behind us, so that's helping us. But really, we have a true robust commercial team now in the U.S., Europe, and Asia Pacific.

We've done a good job in the past, I'd say 18 months, building that team, and that's given us the traction that we're seeing now.

Dan Arias
Analyst, Stifel

Parmeet, CASGEVY, lumpy thing to predict. I know it's just sort of a function of the way that that relationship exists. $1.2 million in the first half of the year. The expectation is for $2 million for the overall year. The label's expanding. I think reimbursement is getting better there. We're in the portion of the session where I ask you about things you haven't really said you're going to talk about yet, which is 2027. But is there any reason why, from what you can see, contributions there next year wouldn't be higher from CASGEVY?

Parmeet Ahuja
CFO, MaxCyte

Yeah. I mean, like you said, we don't want to get ahead of our skis. We've had lots of lessons learned here in 2025 in terms of guidance, so we're going to remain prudent. But it's very heartening to see our customers' success continue to trend very well up towards the right. We are certainly benefactors of that. I would say you can expect growth next year.

Dan Arias
Analyst, Stifel

Okay, great. What does the SPL pipeline look like? I mean, for a while, MaxCyte has had the goal of signing three deals.

There have been years where you've been at three deals halfway through the year.

What would be the right way to think about things from here?

Maher Masoud
CEO, MaxCyte

Yeah. I mean, it is still a healthy pipeline. We are still right now in midst of negotiation, late-stage negotiations with a few companies. This is just the timing. We could sign them maybe this year, maybe early next year. The goal I have given where it is three to five, some years might be less than that, some years more than that. It is timing. But it is a healthy pipeline. There are a few late-stage companies that we are speaking with right now that could sign any time now. So it is still very healthy there, I would say.

Dan Arias
Analyst, Stifel

Okay.

Maher Masoud
CEO, MaxCyte

Yeah.

Dan Arias
Analyst, Stifel

Parmeet, let me just sort of finish with a question on the model and the way that we, on the life sciences side, tend to model these businesses, which is like, you have a box, and then you have got to pull through it on that box. And we use that to guide what we think about revenue growth next year.

Do you think that consumables per revenue per box next year on an annualized basis should be up relative to this year?

Parmeet Ahuja
CFO, MaxCyte

I would say so. I would say so. I mean, we have had challenges, as you know, in the first half of the year, all related to inventory drawdown. Largest customer as well as number of SPLs shutting down. We are getting stability, like I said. If you look at the trend line, over the last trailing 12 months, 6% growth, I would say we should see growth. Yeah.

Dan Arias
Analyst, Stifel

Okay. That is our time. So gentlemen.

Maher Masoud
CEO, MaxCyte

Thank you, Dan.

Dan Arias
Analyst, Stifel

Thank you very much for being here.

Maher Masoud
CEO, MaxCyte

Yeah. Appreciate it.